Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983071 | 0.91 | PKM (0.48) | SMN1; SMN2LMNAALDH1A1HTTMKNK1 | |
| SCHEMBL4985250 | 0.91 | LMNA (0.40) | SMN1; SMN2LMNAKMT2AALDH1A1HTT | |
| SCHEMBL4980438 | 0.90 | MMP1 (0.40) | SMN1; SMN2LMNAKMT2AALDH1A1HTT | |
| SCHEMBL4988452 | 0.89 | MEN1 (0.51) | SMN1; SMN2KMT2AALDH1A1MEN1FAAH | |
| SCHEMBL4989425 | 0.89 | MMP2 (0.40) | SMN1; SMN2LMNAKMT2AALDH1A1HTT | |
| SCHEMBL4982880 | 0.88 | L3MBTL1 (0.42) | SMN1; SMN2LMNAKMT2AALDH1A1HTT | |
| SCHEMBL4987016 | 0.87 | PKM (0.51) | SMN1; SMN2LMNAALDH1A1HTTMKNK1 | |
| SCHEMBL4982847 | 0.84 | LMNA (0.41) | SMN1; SMN2LMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL4985230 | 0.84 | MEN1 (0.43) | KMT2AMEN1 | |
| SCHEMBL4983025 | 0.83 | MEN1 (0.53) | LMNAKMT2AALDH1A1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | SMN1; SMN2 4369/4885LMNA 1911/4885KMT2A 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.